Add-On Pramipexole for the Treatment of Schizophrenia and Schizoaffective Disorder: A Randomized Controlled Trial

Linda Levi, BSc^a ; Daisy Zamora, PhD^b ; Igor Nastas, MD^c ; Ilan Gonen, MD^d ; Paull Radu, MD^d ; Valentin Matei, MD^e ; Adela M. Ciobanu, MD^e ; Anatol Nacu, MD^c ; Larisa Boronin, MD^c ; Lusian Karakrah, MD^a ; Michael Davidson, MD^f ; John M. Davis, MD^g ; Mark Weiser, MD^a,h

J Clin Psychiatry 2022;83(5):21m14233

ABSTRACT

Objective: Several small clinical trials have reported that the dopamine agonist pramipexole was beneficial in treating patients with schizophrenia. A confirmatory trial was conducted to test this hypothesis.

Methods: This 16-week, multicenter, double-blind, randomized, placebo-controlled study included 200 subjects meeting DSM-IV-TR criteria for schizophrenia or schizoaffective disorder. Patients were randomized to receive either pramipexole (0.75 mg twice daily, n = 100) or placebo (n = 100) as an add-on to their regular antipsychotic treatment. The primary outcome measure was the total score on the Positive and Negative Syndrome Scale (PANSS); secondary outcome measures included PANSS subscale and cognitive functioning scores. Recruitment was performed in 30 sites in Romania and 1 site in the Republic of Moldova between January and June 2011.

Results: Analysis of covariance models showed no significant difference between pramipexole and placebo for total PANSS (P > .99) and PANSS positive (P > .99), negative (P = .73), and general psychopathology (P = .99) subscale scores. Changes in Clinical Global Impressions–Severity of Illness scale and Brief Assessment of Cognition in Schizophrenia scores showed no significant difference between pramipexole and placebo.

Conclusions: The results of this large randomized controlled trial indicated that pramipexole was not efficacious as an add-on to antipsychotic medications for schizophrenia.

Trial Registration: ClinicalTrials.gov identifier NCT01320982

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

Buy PDF for $40

Please sign in or purchase this PDF for $40.

References (26)

Guillin O, Abi-Dargham A, Laruelle M. Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol. 2007;78:1–39. PubMed CrossRef
Maia TV, Frank MJ. An integrative perspective on the role of dopamine in schizophrenia. Biol Psychiatry. 2017;81(1):52–66. PubMed CrossRef
Chong TT, Husain M. The role of dopamine in the pathophysiology and treatment of apathy. Prog Brain Res. 2016;229:389–426. PubMed CrossRef
Mierau J, Schneider FJ, Ensinger HA, et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol. 1995;290(1):29–36. PubMed CrossRef
Kasper S, Barnas C, Heiden A, et al. Pramipexole as adjunct to haloperidol in schizophrenia: safety and efficacy. Eur Neuropsychopharmacol. 1997;7(1):65–70. PubMed CrossRef
Kelleher JP, Centorrino F, Huxley NA, et al. Pilot randomized, controlled trial of pramipexole to augment antipsychotic treatment. Eur Neuropsychopharmacol. 2012;22(6):415–418. PubMed CrossRef
Sabe M, Kirschner M, Kaiser S. Prodopaminergic drugs for treating the negative symptoms of schizophrenia: systematic review and meta-analysis of randomized controlled trials. J Clin Psychopharmacol. 2019;39(6):658–664. PubMed CrossRef
Weiser M, Levi L, Burshtein S, et al. The effect of minocycline on symptoms in schizophrenia: results from a randomized controlled trial. Schizophr Res. 2019;206:325–332. PubMed CrossRef
Weiser M, Zamora D, Levi L, et al. Adjunctive aspirin vs placebo in patients with schizophrenia: results of two randomized controlled trials. Schizophr Bull. 2021;47(4):1077–1087. PubMed CrossRef
Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. PubMed CrossRef
Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised CGI Clinical Global Impressions. US Department of Health; 1976:76–339.
Keefe RS, Goldberg TE, Harvey PD, et al. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68(2-3):283–297. PubMed CrossRef
Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand suppl. 1987;334(s334):1–100. PubMed CrossRef
Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand suppl. 1970;212(S212):11–19. PubMed CrossRef
Golmirzaei J, Mahboobi H, Yazdanparast M, et al. Psychopharmacology of attention-deficit hyperactivity disorder: effects and side effects. Curr Pharm Des. 2016;22(5):590–594. PubMed CrossRef
Weng JJ, Wang LH, Zhu H, et al. Efficacy of low-dose D₂/D₃ partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study. Neuropsychiatr Dis Treat. 2019;15:2195–2203. PubMed CrossRef
Burdick KE, Braga RJ, Nnadi CU, et al. Placebo-controlled adjunctive trial of pramipexole in patients with bipolar disorder: targeting cognitive dysfunction. J Clin Psychiatry. 2012;73(1):103–112. PubMed CrossRef
Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216–229. PubMed CrossRef
Egerton A, Murphy A, Donocik J, et al. Dopamine and glutamate in antipsychotic-responsive compared with antipsychotic-nonresponsive psychosis: a multicenter positron emission tomography and magnetic resonance spectroscopy study (STRATA). Schizophr Bull. 2021;47(2):505–516. PubMed CrossRef
Fawcett J, Rush AJ, Vukelich J, et al. Clinical experience with high-dosage pramipexole in patients with treatment-resistant depressive episodes in unipolar and bipolar depression. Am J Psychiatry. 2016;173(2):107–111. PubMed CrossRef
Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry. 2004;161(3):564–566. PubMed CrossRef
Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004;56(1):54–60. PubMed CrossRef
Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety. 2000;11(2):58–65. PubMed CrossRef
Cusin C, Iovieno N, Iosifescu DV, et al. A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder. J Clin Psychiatry. 2013;74(7):e636–e641. PubMed CrossRef
Tundo A, de Filippis R, De Crescenzo F. Pramipexole in the treatment of unipolar and bipolar depression: a systematic review and meta-analysis. Acta Psychiatr Scand. 2019;140(2):116–125. PubMed CrossRef
Volkow ND, Morales M. The brain on drugs: from reward to addiction. Cell. 2015;162(4):712–725. PubMed CrossRef